41 invested enterprises have been selected into the 2024 China Biopharmaceutical Top 100 List

　　Recently, at the 2024 China Pharmaceutical Industry Development Conference - Biomedical Industry Investment and Financing Forum, the 2024 China Biomedical Industry Top 100 list was officially released. 41 companies invested by Xi Chuang Capital, including Dano Pharmaceuticals, Xian Tong Biotech, Zhenhe Technology, Shengde Medical, and Keya Medical, were honored to be selected.

　　In terms of list compilation, a combination of selection and recommendation systems is adopted. In data collection, a combination of public information and field research is employed. In evaluation, a combination of model scoring and expert review is utilized. We strive to ensure scientific selection of "in" and "out", reasonable ranking of finalists, and balance between leading enterprises that "take big steps forward" and innovative enterprises that "take small but quick steps".

　　Currently, China's pharmaceutical industry has transitioned from a phase of "general innovation" to an era of "selecting high-quality innovation". In the field of biomedicine, there is a widespread deployment of next-generation drugs such as cell therapy, gene therapy, polyclonal/bispecific antibodies, ADCs, PROTACs, and nucleic acid drugs. In the medical device sector, breakthrough innovations such as high-end imaging equipment, surgical navigation and robots, high-throughput sequencing, and brain-computer interfaces are emerging endlessly. In the digital healthcare field, AI-based pharmaceuticals, telemedicine, and digital therapies are expanding and enriching application scenarios, while promoting the dissemination of high-quality medical resources and benefiting more patients. Xichuang Investment targets enterprises with innovative technologies in biomedicine, leveraging capital advantages such as the Wuxi Biomedical Industry Fund in Jiangsu Province, and collaborating with municipal healthcare groups to establish joint ventures. By focusing on industrial investment funds and major project introductions, and through operational models such as "parks within parks", it attracts high-quality, high-growth enterprises to continuously gather in major biomedicine parks in Wuxi, achieving industrial development from "complete chain" to "optimized ecosystem".